Combining sorafenib and CDK5 inhibition, either by genetic KD by short hairpin RNA (shRNA), or pharmacologic inhibition with dinaciclib (a.k.a SCH-727965), synergistically compromised HCC progression in vitro or in an in vivo animal model [178]. This evidence concerns the gene CDK5 and hepatocellular carcinoma.